CQDM - KEY ELEMENTS OF OUR CONTRIBUTION TO QUEBEC AND CANADA'S ECONOMY

A promising projects portfolio

Over $274 M raised

Since its foundation in 2008, our biopharmaceutical research consortium has funded innovation by raising over $274 M in total contributions from:

  • 13 of the largest pharmaceutical companies in the world: Merck, Pfizer, AstraZeneca, Boehringer Ingelheim, Eli Lilly Canada, GlaxoSmithKline, Janssen, Novartis Pharma Canada, Sanofi Canada, Servier, Roche, Takeda and Amgen;
  • The Ministère de l’Économie et de l’Innovation (MEI) of the Government of Quebec;
  • The Business Led-Networks of Centres of Excellence (BL-NCE) program of the Government of Canada;
  • The co-funding partners.

To date, CQDM has established 18 funding programs and launched 86 calls for proposals.

Collaborative research at its best

To date, CQDM boasts:

  • 110 outstanding research projects;
    • carried out by a network of more than 1761 researchers, equivalent to 1411 FTE* x year including 383 graduate and post-graduate students;
    • in 119 research institutions (50 public and 69 private);
    • engaging 150 mentors from CQDM’s pharmaceutical member companies;
    • for a total of $132 M invested in R&D by CQDM.

(*FTE: Full-Time Equivalent)

Convincing results

The results to date speak for themselves, with technologies that accelerate drug discovery and generate significant socioeconomic benefits, including:

  • 71 successfully completed projects achieving 86% of deliverables;
  • CQDM pharmaceutical partners committing significant additional contributions to several research laboratories to further develop CQDM technologies;
  • launch of 9 start-ups in the life sciences sector;
  • $571 M in additional investments for researchers.

CQDM builds on more than a decade of success!